SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementi... See more
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 m... See more
SLS
SELLAS Life Sciences Group Inc
-63.99%
$3.61 - $1.30
Feb 7th 2023 - Mar 21st 2023
Mar, 20, 2023
It reported positive outcomes in pleural mesotheli... See more
Mar, 20, 2023
PROC data are excellent compared to any combo trials.
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.
Feb, 1, 2023
The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.
Jan, 17, 2023
$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.
Jan, 6, 2023
$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.
Jan, 4, 2023
$SAVA , VERA announced positive phase 2b results meeting primary end point.
Dec, 27, 2022
My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients
Mar, 20, 2023
It reported positive outcomes in pleural mesothelioma patients, including: Improved survival: Study patients lived around 11 months.
Mar, 20, 2023
PROC data are excellent compared to any combo trials.
Mar, 8, 2023
But yesterdays paper also has me considering, if there isn't a deal with $mrk or $BMY or some other CPI BP --- That data is Best In Class - best in clinic, best in trial too.
Mar, 3, 2023
phase II results within weeks!!!
Feb, 27, 2023
Now phase 3 trial is showing similar results to date where patients are living longer after Galinpepimut-S up to 1.5 year longer is a breakthrough for AML patients.
Feb, 6, 2023
Positive trial data/results supported with bullish news and sentiment! 4.
Jan, 24, 2023
The nation’s best means the O'Neal Comprehensive Center in Alabama have access to the latest therapies, cutting-edge clinical trials and the expertise needed to treat their cancer.
Jan, 24, 2023
Gps is doing what it has done in every single trial and its the reason Patients are living 3 fold longer than patients on best available treatments.
Jan, 11, 2023
Treatment with GFH009 resulted in 90 to 100 percent cancer inhibition at dose levels equivalent to those already demonstrated to be safe in patients in the ongoing Phase 1 trial with no viable cancer cells at the highest dose levels.